LOAR Q1 2026 Earnings Massive EPS Beat Signals Strong Execution Revenue Data Not Reported AA Q1 2026 Earnings EPS Misses Estimates Shares Climb on Strategic Optimism BOXL Q1 2026 Earnings EPS Beat of 66 Highlights Cost Control Efforts Processa Pharmaceuticals PCSA Q4 2025 Earnings EPS Misses Estimates by a Wide Margin as PreRevenue Biotech Advances Pipeline BMY Q1 2026 Earnings EPS Beat on Cost Discipline and Operational Execution Mesa Royalty Trust MTR Q4 2025 Earnings Modest EPS as Royalty Income Continues to Reflect Stable Production